image dons

je fais un don

High doses of clopidogrel to overcome genetic resistance: the randomized crossover CLOVIS-2 (Clopidogrel and Response Variability Investigation Study 2).

Colloquium "Rythme et conduction" (23 avril 2024)
Programme et inscription, c'est ici !

Bourses ACTION 2024 - Prix de Recherche JP Collet et Y Grosgogeat - PHRA 2024
M2, thèse de sciences, mobilité et soins infirmiers : deadline 15 mars - PHRA : deadline 30 mars

La Grande Journée du Coeur - Rendez-vous dans un cadre exceptionnel : l'Eglise Saint-Louis de la Pitié-Salpêtrière le jeudi 27 juin 2024
A vos agendas !

High doses of clopidogrel to overcome genetic resistance: the randomized crossover CLOVIS-2 (Clopidogrel and Response Variability Investigation Study 2).

Publié dans JACC : Cardiovascular Interventions, le 01 avril 2011.

En savoir plus en consultant le site.

Auteurs : Collet JP, Hulot JS, Anzaha G, Pena A, Chastre T, Caron C, Silvain J, Cayla G, Bellemain-Appaix A, Vignalou JB, Galier S, Barthélémy O, Beygui F, Gallois V, Montalescot G; CLOVIS-2 Investigators.

Abstract

OBJECTIVES:

This study sought to determine whether the pharmacokinetic (PK) and pharmacodynamic (PD) responses to high or standard clopidogrel loading doses (LDs) differ according to CYP2C19*2 allele.

BACKGROUND:

CYP2C19 loss-of-function alleles are associated with reduced responsiveness to standard clopidogrel doses.

METHODS:

Young post-myocardial infarction patients heterozygous (wild type [wt]/*2, n = 43) or homozygous (*2/*2, n = 8) for the CYP2C19*2 genetic variant were matched with patients not carrying the variant (wt/wt, n = 58). All patients were randomized to a 300- or 900-mg clopidogrel LD. The relative reduction in residual platelet aggregation (RR-RPA, %) and the area under the plasma concentration time curve of active metabolite from baseline to 6 h after loading (AUC(0-6)) were compared according to both LD and CYP2C19*2 carriage.

RESULTS:

The 300-mg LD led to a gene-dose effect for RR-RPA (-65.7% ± 35.9% in wt/wt vs. -48.0% ± 38.4% in wt/*2 vs. -14.6% ± 32.4% in *2/*2; overall p value = 0.003, p = 0.03 for wt/wt versus wt/*2, p = 0.04 for wt/*2 versus *2/*2) with minor effect in *2/*2 carriers. After the 900-mg LD, the effect of the CYP2C19*2 variant on platelet inhibition was fully compensated in wt/*2 carriers but not in *2/*2 carriers (-83.6% ± 25.8% in wt/wt vs.-77.2% ± 26.9% in wt/*2 vs. -29.5% ± 26.8% in *2/*2; overall p value = 0.0003, p = 0.20 for wt/wt versus wt/*2, p < 0.001 for wt/*2 versus *2/*2). A similar pattern was observed for the active metabolite AUC(0-6) according to carriage of CYP2C19*2 for both LDs. There was a significant correlation between PK and PD responses irrespective of the LD.

CONCLUSIONS:

Carriers of CYP2C19*2 display significantly lower responses to clopidogrel with a gene-dose effect. Clopidogrel resistance can be overcome by increasing the dose in heterozygous carriers but not in homozygous carriers. (Clopidogrel and Response Variability Investigation Study 2 [CLOVIS-2]; NCT00822666).

 

Autres actualités

+

01/10/2023


Rationale and design of the ARAMIS trial: Anakinra versus pl...

Arch Cardiovasc Dis. 2023 Oct;116(10):460-466
+

01/09/2023


Comparison of three echo-guidance techniques in percutaneous...

Arch Cardiovasc Dis. 2023 Sep 29:S1875-2136(23)00171-7